Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (551-560 of 745) with videos related to

Pageof 75
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumorsKyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
The Lancet. Oncology|April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M Syeda, Georgina V Long, James Garrett, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
The Journal of Investigative Dermatology|September 2, 2011
Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patientsWilliam M Lin, Julia M Lewis, Renata B Filler, et al.
Journal of Translational Medicine|October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabDomenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
Cancers|July 14, 2023
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter StudyDirk Tomsitz, Theresa Ruf, Markus Heppt, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Blood|January 7, 2011
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascadeMichael K Kiessling, Patrick A Oberholzer, Chandrani Mondal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsDaniel E Speiser, Katrin Schwarz, Petra Baumgaertner, et al.
European Journal of Dermatology : EJD|January 31, 2019
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Karen Bartley, Thomas Karagiannis, et al.
Pageof 75

Showing results (551-560 of 745) with videos related to

Sort By:
Pageof 75
European Journal of Cancer (Oxford, England : 1990)|May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumorsKyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
The Lancet. Oncology|April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trialMahrukh M Syeda, Georgina V Long, James Garrett, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaDirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
The Journal of Investigative Dermatology|September 2, 2011
Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patientsWilliam M Lin, Julia M Lewis, Renata B Filler, et al.
Journal of Translational Medicine|October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabDomenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
Cancers|July 14, 2023
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter StudyDirk Tomsitz, Theresa Ruf, Markus Heppt, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Blood|January 7, 2011
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascadeMichael K Kiessling, Patrick A Oberholzer, Chandrani Mondal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsDaniel E Speiser, Katrin Schwarz, Petra Baumgaertner, et al.
European Journal of Dermatology : EJD|January 31, 2019
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Karen Bartley, Thomas Karagiannis, et al.
Pageof 75